Avantor (AVTR) Fell: Destocking Cycle Extends Beyond Forecasts

Broyhill Asset Management disclosed in its first-quarter 2026 investor letter that its equity composite fell 6.0% net of fees, trailing the MSCI All Country World Index, which dropped 3.1%. The fund explicitly tied the underperformance to an extended destocking cycle in the life sciences tools sector, with Avantor (AVTR) bearing the brunt of the slowdown.

The letter confirms what sell-side notes have been signalling for two quarters: the inventory correction at Avantor's laboratory and biopharma customers is not resolving as quickly as many hoped. Destocking – the process of clients running down existing stockpiles rather than placing new orders – has been a persistent headwind across the sector. Broyhill's report suggests the duration of this phase is testing even patient investors.

The Inventory Problem That Won't Quit

Destocking in life sciences tools follows a predictable pattern. After pandemic-era hoarding, end users slowed purchases to normalise inventories. The typical cycle lasts three to four quarters. Avantor's management flagged the issue in early 2025. By the start of 2026, the drag was expected to fade. Broyhill's experience shows the recovery has not arrived.

What changed: demand signals from bioprocessing and lab consumables remain weak. Customers are still citing budget conservatism and lower utilisation of existing reagent and equipment stocks. The mechanism is straightforward – Avantor's revenue is directly tied to the volume of consumables and chemicals flowing through research and manufacturing sites. When those sites stop buying, revenue drops and margins compress on fixed cost leverage.

The better market read: this is not a structural problem for Avantor. The company's $6.8 billion annual revenue base, its position in essential reagents, and its distribution network give it long-term relevance. The issue is timing. A prolonged destocking phase delays the earnings rebound, forcing investors to push out valuation recovery. For a stock priced on near-term earnings power, the wait creates downside risk until concrete replenishment data emerges.

Broyhill's letter matters because it comes from a value-oriented manager known for long holding periods. If they are cutting exposure or marking down their thesis, it raises questions about consensus expectations. The fund's 6.0% first-quarter loss is roughly 300 basis points of underperformance per month – a pace that typically triggers portfolio repositioning.

What Signals a Turn for Avantor

Investors watching AVTR should focus on two concrete markers. First, commentary from large life sciences distributors like Thermo Fisher or Danaher on end-market demand trends. Second, Avantor's own quarterly filings should show a sequential improvement in organic growth rates. The Broyhill letter implies that neither milestone has been hit yet.

Any announcement of a major contract win or a capacity expansion by a biopharma client would also be a positive catalyst, as it would signal new orders flowing through. Conversely, continued downgrades from sell-side firms such as the Evercore ISI price target cut to $8.50 reinforce the headwind.

For now, the Avantor story remains a waiting game. The destocking cycle will end – inventory cannot shrink indefinitely. The open question is whether the next two quarters bring relief or more disappointment.

AlphaScala data shows AVTR's Alpha Score at 46/100, a Mixed label in the Financial Services sector. The score reflects the stock's neutral positioning amid the prolonged inventory correction. Investors can track the stock on the MSCI stock page and review related analysis on the Evercore ISI price target cut.

The next decision point for AVTR holders is the company's next quarterly filing. If organic growth shows a sequential uptick, the destocking narrative weakens. If the trend flatlines, the stock may face another leg down as the market reprices the recovery timeline.